This study tests two forms of buprenorphine treatment, extended-release buprenorphine (XR-B) and sublingual buprenorphine (SL-B) for adults with opioid use disorder (OUD) who are returning to the community from jail. The study treatment will be delivered via telemedicine both in jail and in the community. The treatment starts in jail and continues for six months after release, with a safety visit at seven months post-release and a long-term follow-up at 12 months post-release. To reduce barriers to treatment access, in conjunction with telemedicine treatment, prescriptions for SL-B will be filled at local pharmacies and XR-B injections will be administered by local pharmacies. through telemedicine at local pharmacies, with follow-up safety checks. Effectiveness outcomes include treatment retention, reduced drug use, decreases in overdose incidents, improved health quality, lower HIV risk behaviors, and reduced criminal activities. The study also evaluates the effectiveness of the telemedicine approach in jail and pharmacy settings and how it can be sustained. This study is the first large-scale patient-preference trial of XR-B/SL-B using telemedicine among individuals leaving jail and the first study of continued XR-B injections administered to a reentry population at pharmacies.